Key Points
-
The idea that inhibiting tumour angiogenesis might be an effective anticancer strategy was proposed by Folkman over thirty years ago.
-
A number of molecules involved in angiogenesis have now been identified, including vascular endothelial growth factor (VEGF), which is an essential regulator of normal and pathological angiogenesis.
-
This article overviews the biology of VEGF, and then focuses on the path from the identification of VEGF and the establishment of its key role in tumour angiogenesis to the clinical development of the humanized anti-VEGF monoclonal antibody bevacizumab.
-
Bevacizumab was approved by the FDA as a first-line treatment for metastatic colorectal cancer in February 2004 — the first approval by the FDA of a therapeutic developed to target tumour angiogenesis.
Abstract
The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular supply to nourish a growing tumour, was postulated many decades ago, although the identification and isolation of these factors proved elusive. Now, vascular endothelial growth factor (VEGF), which was identified in the 1980s, is recognized as an essential regulator of normal and abnormal blood vessel growth. In 1993, it was shown that a monoclonal antibody that targeted VEGF results in a dramatic suppression of tumour growth in vivo, which led to the development of bevacizumab (Avastin; Genentech), a humanized variant of this anti-VEGF antibody, as an anticancer agent. The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumour angiogenesis and that blocking angiogenesis is an effective strategy to treat human cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. Cancer 2, 795–803 (2002).
Ide, A. G., Baker, N. H. & Warren, S. L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 42, 891–899 (1939).
Algire, G. H., Chalkley, H. W., Legallais, F. Y. & Park, H. D. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl Cancer Inst. 6, 73–85 (1945).
Greenblatt, M. & Shubick, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
Ehrmann, R. L. & Knoth, M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J. Natl. Cancer Inst. 41, 1329–1341 (1968).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Folkman, J., Merler, E., Abernathy, C. & Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275–288 (1971).
Gullino, P. M. Angiogenesis and oncogenesis. J. Natl Cancer Inst. 61, 639–643 (1978).
Folkman, J. & Klagsbrun, M. Angiogenic factors. Science 235, 442–447 (1987).
Klagsbrun, M. & D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217–239 (1991).
Gospodarowicz, D., Ferrara, N., Schweigerer, L. & Neufeld, G. Structural characterization and biological functions of fibroblast growth factor. Endocrin. Rev. 8, 95–114 (1987).
Matsuzaki, K., Yoshitake, Y., Matuo, Y., Sasaki, H. & Nishikawa, K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc. Natl Acad. Sci. USA 86, 9911–9915 (1989).
Dennis, P. A. & Rifkin, D. B. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J. Cell. Physiol. 144, 84–98 (1990).
Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA 88, 9267–9271 (1991).
Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576–2581 (1996).
Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR–2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).
Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl Acad. Sci. USA 93, 11675–11680 (1996).
Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685–693 (2003).
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E. & Alitalo, K. Lymphangiogenesis and cancer metastasis. Nature Rev. Cancer 2, 573–583 (2002).
Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
Connolly, D. T. et al. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 264, 20017–20024 (1989).
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309–1312 (1989).
Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806–1814 (1991).
Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947–11954 (1991).
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031–26037 (1992).
Park, J. E., Keller, G. -A. & Ferrara, N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317–1326 (1993).
Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16, 2684–2698 (2002).
Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocrin. Rev. (in the press).
Keyt, B. A. et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271, 7788–7795 (1996).
Pepper, M. S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86, 346–355 (2001).
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).
Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrin. Rev. 18, 4–25 (1997).
Plouet, J., Schilling, J. & Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 8, 3801–3808 (1989).
Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002).
Melder, R. J. et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med. 2, 992–997 (1996).
Gerber, H. P. et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30366–30343 (1998).
Gerber, H. P., Dixit, V. & Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273, 13313–13316 (1998).
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).
Carmeliet, P. Blood vessels and nerves: common signals, pathways and diseases. Nature Rev. Genet. 4, 710–720 (2003).
Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 5, 519–524 (1990).
de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989–991 (1992).
Terman, B. I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187, 1579–1586 (1992).
Millauer, B. et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835–846 (1993).
Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. & Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA 90, 7533–7537 (1993).
Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66–70 (1995).
Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995).
Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646–25654 (1994).
Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 8, 841–849 (2002).
Gerber, H. -P. et al. Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958 (2002).
Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336–3343 (1996).
Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 8, 831–840 (2002).
Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289–300 (2002).
LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890–893 (2003).
Autiero, M., Luttun, A., Tjwa, M. & Carmeliet, P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemost. 1, 1356–1370 (2003).
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735–745 (1998).
Safran, M. & Kaelin, W. J. Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111, 779–783 (2003).
Semenza, G. L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54, 17–28 (2003).
Mole, D. R., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Regulation of HIF by the von Hippel–Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52, 43–47 (2001).
Lonser, R. R. et al. von Hippel–Lindau disease. Lancet 361, 2059–2067 (2003).
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
Ivan, M. et al. HIF-α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).
Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677–684 (2003).
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. & Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270, 25915–25919 (1995).
Okada, F. et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras upregulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl Acad. Sci. USA. 95, 3609–3614 (1998).
Shi, Y. -P. & Ferrara, N. Oncogenic ras fails to restore an in vivo oncogenic phenotype in embryonic stem cells lacking VEGF. Biochem. Biophys. Res. Commun. 254, 480–483 (1999).
Zhang, X., Gaspard, J. P. & Chung, D. C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61, 6050–6054 (2001).
Seno, H. et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62, 506–511 (2002).
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K. & DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589–1594 (2000).
Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nature Med. 7, 1048–1051 (2001).
Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996).
Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435–439 (1996).
Gerber, H. P. et al. VEGF is required for growth and survival in neonatal mice. Development 126, 1149–1159 (1999).
Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707–716 (2003).
Gerber, H. P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med. 5, 623–628 (1999).
Ryan, A. M. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. 27, 78–86 (1999).
Bassett, D. L. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am. J. Anat. 73, 251–278 (1943).
Phillips, H. S., Hains, J., Leung, D. W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127, 965–967 (1990).
Ravindranath, N., Little-Ihrig, L., Phillips, H. S., Ferrara, N. & Zeleznik, A. J. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131, 254–260 (1992).
Zimmermann, R. C. et al. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J. Clin. Endocrinol. Metab. 86, 768–772 (2001).
Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med. 4, 336–340 (1998).
Fraser, H. M. et al. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141, 995–1000 (2000).
Hazzard, T. M., Xu, F. & Stouffer, R. L. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol. Reprod. 67, 1305–1312 (2002).
Volm, M., Koomagi, R. & Mattern, J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer 74, 64–68 (1997).
Yoshiji, H., Gomez, D. E., Shibuya, M. & Thorgeirsson, U. P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56, 2013–2016 (1996).
Ellis, L. M. et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 34, 337–340 (1998).
Tomisawa, M. et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer 35, 133–137 (1999).
Sowter, H. M. et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Invest. 77, 607–614 (1997).
Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843–845 (1992).
Plate, K. H., Breier, G., Weich, H. A. & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845–848 (1992).
Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841–844 (1993). The earliest study to demonstrate that blocking VEGF suppresses angiogenesis and tumour growth in vivo.
Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A. & Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789–1797 (1995).
Melnyk, O., Shuman, M. A. & Kim, K. J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 56, 921–924 (1996).
Borgstrom, P., Hillan, K. J., Sriramarao, P. & Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56, 4032–4039 (1996).
Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P. & Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35, 1–10 (1998).
Borgstrom, P., Gold, D. P., Hillan, K. J. & Ferrara, N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19, 4203–4214 (1999).
Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–579 (1994). This study demonstrated for the first time the key role of VEGFR2 signalling in tumour angiogenesis.
Strawn, L. M. et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540–3545 (1996).
Wood, J. M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–2189 (2000).
Wedge, S. R. et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 60, 970–975 (2000).
Saleh, M., Stacker, S. A. & Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, 393–401 (1996).
Oku, T. et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58, 4185–4192 (1998).
Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A. & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253–6258 (2000).
Kuo, C. J. et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA 98, 4605–4610 (2001).
Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).
Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715–725 (1998).
Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α—> hypoxia response element—> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248–6252 (2000).
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H. P. & Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β-cell carcinogenesis. Cancer Cell 1, 193–202 (2002). The first evidence that VEGF inhibition results in tumour suppression in a genetic model of cancer.
Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3, 401–410 (2003).
Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000). The study shows that VEGF blockade amplifies the effects of chemotherapy by blunting a key survival signal for endothelial cells.
Lee, C. G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
Kozin, S. V. et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001).
Pham, C. D. et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16, 225–230 (1998).
Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004). The study demonstrates that blocking VEGF has direct antivascular effects in colorectal cancer patients.
Presta, L. G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
Muller, Y. A. et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure 6, 1153–1167 (1998).
Lin, Y. S. et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288, 371–378 (1999).
Davis-Smyth, T., Chen, H., Park, J., Presta, L. G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919–4927 (1996).
Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197–11204 (1998).
Kim, E. S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399–11404 (2002).
Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
Shima, D. T. et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest. Ophthalmol. Vis. Sci. 37, 1334–1340 (1996).
Margolin, K. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851–856 (2001).
Gordon, M. S. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
Reese, D. M. et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J. 3, 65–70 (2001).
Cobleigh, M. A. et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30, 117–124 (2003).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003). The first placebo-controlled study to show that blocking VEGF with bevacizumab has a clinical benefit in cancer patients.
Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).
DeVore, R. et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. A1896 (2000).
Saltz, L. B. et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6, 81–91 (2001).
Hurwitz, H. et al. A phase III randomized trial to evaluate the safety and efficacy of adding bevacizumab (rhuMAb VEGF) to bolus IFL in first line metastatic colorectal cancer. N. Engl. J. Med. (in the press). A key study that demonstrates that adding bevacizumab to chemotherapy confers a significant survival advantage to patients with previously untreated metastatic colorectal cancer.
Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).
Garber, K. Angiogenesis inhibitors suffer new setback. Nature Biotechnol. 20, 1067–1068 (2002).
Smith, J. K., Mamoon, N. M. & Duhe, R. J. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14, 175–225 (2004).
Richly, H. et al. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 41, 620–621 (2003).
Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003).
Ruckman, J. et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273, 20556–20567 (1998).
Puliafito, C. The anti-VEGF aptamer approach: the macugen collaborative trial. Proc. Am. Acad. Ophthalmol. Subspecialty Day. The Retina Debates 2003: New Technology & Controversies from the Posterior Segment, Anaheim, California. 183–185 (2003).
Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865–881 (1999).
Goldberg, R. M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23–30 (2004).
Miller, K. D. et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastine) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. 76, S37 (2002).
Kindler, L. et al. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer. Proc. Am Soc. Clin. Oncol. 22, 259 (2003).
Carson, W. E. et al. A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proc. Am. Soc. Clin. Oncol. A705 (2003).
Herbst, R. S. et al. Phase I/II triall evaluating blockage of tumour blood supply and tumour cell proliferation with combines bevacizumab and erlotinib HCI as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer 1, S293 (2003).
Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002).
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955–3964 (2003).
Gerber, H. P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20–31 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.F., K.J.H., H.-P.G. and W.N. are employees of Genentech, Inc., which developed and markets bevacizumab (Avastin).
Glossary
- ENDOTHELIAL CELLS
-
The main type of cell in the inside lining of blood vessels, lymph vessels and the heart.
- HEPARIN
-
Naturally occurring acidic glycosaminoglycan. Heparin-like moieties are common in proteoglycans in the cell surface and extracellular matrix.
- PERICYTES
-
Support cells of capillaries (believed by many to be the equivalent of smooth muscle cells in larger vessels).
- DOMINANT-NEGATIVE
-
A defective protein that retains interaction capabilities and so distorts or competes with normal proteins, inhibiting their function.
- XENOGRAFTS
-
Tumour specimens can be grown in immunocompromised rodents to provide tumour models with many of the complexities of human tumours.
- HUMANIZATION
-
A technique used to circumvent the immunogenicity of murine monoclonal antibodies for human therapy. In the simplest case, the complementary determining regions of a mouse monoclonal antibody are transferred to a human antibody that therefore acquires the binding characteristics of the original murine antibody. The amino-acid sequence of the humanized antibody is 93–95% human.
- TORTUOSITY
-
The characteristic serpiginous appearance of newly formed and tumour-associated vessels. In tumour vessels, tortuosity is believed to be a hallmark of defective structural properties.
- APTAMER
-
Oligonucleotide ligand selected in vitro to bind specific proteins.
Rights and permissions
About this article
Cite this article
Ferrara, N., Hillan, K., Gerber, HP. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3, 391–400 (2004). https://doi.org/10.1038/nrd1381
Issue Date:
DOI: https://doi.org/10.1038/nrd1381
This article is cited by
-
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease
Translational Neurodegeneration (2024)
-
Therapy-induced modulation of tumor vasculature and oxygenation in a murine glioblastoma model quantified by deep learning-based feature extraction
Scientific Reports (2024)
-
Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme
BMC Cancer (2023)
-
A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin® in healthy Chinese male subjects
BMC Pharmacology and Toxicology (2023)
-
Inhibition of MMPs supports amoeboid angiogenesis hampering VEGF-targeted therapies via MLC and ERK 1/2 signaling
Journal of Translational Medicine (2023)